Gastrointestinal Carcinoid Tumors Research

  • FDA Approves New Treatment for Certain Neuroendocrine Tumors
    Posted: February 8, 2018

    People with cancerous neuroendocrine tumors (NETs) that affect the digestive tract now have a new treatment option. On January 29, FDA approved the targeted treatment lutetium Lu 177 dotatate (Lutathera®) for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract.